Opko Health announced that the Food and Drug Administration (FDA) has accepted for review the New Drug Application (NDA) for Rayaldee (calcifediol modified-release capsules) for the prevention and treatment of secondary hyperparathyroidism (SHPT) in patients with stage 3 or 4 chronic kidney disease (CKD) and vitamin D insufficiency.

The NDA is supported by data from three randomized, double-blind, placebo-controlled studies and one open-label extension study conducted in the targeted patient population. These studies met all primary efficacy and safety endpoints.

RELATED: ECG Metrics May Predict Cardiac Deaths in CKD Patients

Rayaldee is an oral vitamin D prohormone treatment. It has a proprietary modified-release formulation designed to gradually and reliably raise serum total 25-hydroxyvitamin D (prohormone) concentrations to targeted levels (at least 30 ng/mL) while avoiding upregulation of CYP24A1, a cytochrome P-450 enzyme which interferes with the desired parathyroid hormone (PTH)-lowering effect. Gradual elevation of serum total 25-hydroxyvitamin D is intended to prevent excessive elevation of serum calcium and related vascular and renal calcification.

For more information visit Opko.com.